Calithera Biosciences Inc. (CALA) Stock Price Down 1.9%
Calithera Biosciences Inc. (NASDAQ:CALA)’s share price fell 1.9% during mid-day trading on Friday . The stock traded as low as $3.02 and last traded at $3.14, with a volume of 121,706 shares trading hands. The stock had previously closed at $3.20.
Several brokerages recently issued reports on CALA. JMP Securities reissued a “buy” rating on shares of Calithera Biosciences in a report on Wednesday, June 8th. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, May 17th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a report on Thursday, May 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $10.38.
The stock’s market cap is $60.09 million. The stock has a 50-day moving average of $3.76 and a 200-day moving average of $4.99.
Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.05. On average, equities research analysts anticipate that Calithera Biosciences Inc. will post ($2.15) EPS for the current fiscal year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.